Comparative Pharmacology
Head-to-head clinical analysis: ERYTHROCIN versus ERYTHROMYCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYTHROCIN versus ERYTHROMYCIN STEARATE.
ERYTHROCIN vs ERYTHROMYCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also exhibits anti-inflammatory and prokinetic effects via motilin receptor agonism.
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptides.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6 hours.
250-500 mg orally every 6 hours or 500-1000 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5-2 hours in adults; may prolong to 4-6 hours in hepatic impairment or neonates.
1.4-2 hours in adults with normal renal function; prolonged to 5-6 hours in anuria; unchanged in hepatic impairment.
Primarily eliminated via biliary excretion as unchanged drug and metabolites; approximately 2-5% excreted renally as active drug, 15-20% as metabolites; up to 30% excreted in feces.
Primarily excreted in bile as active drug; about 2-5% excreted renally as unchanged drug. Up to 15% excreted in feces.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic